Efficacy and safety of pilocarpine / sodium alginate formulation for dry mouth in Sjogren's syndrome patients

Not Applicable

• Conditions: Sjogren' s syndrome

• Registration Number: JPRN-UMIN000029307
• Lead Sponsor: Teikyo University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-09-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with ischemic heart disease 2. Patients with asthma or chronic obstructive airway disease 3. Patients with gastrointestinal obstruction or bladder neck obstruction 4. Patients with epilepsy 5. Patients with parkinsonism or Parkinson's disease 6. Patients with iritis 7. Patients with hypersensitivity on pilocarpine or arginine 8. Patients administered with pilocarpine hydrochloride within 6.5 hours 9. Patients administered with cevimeline hydrochloride hydrate within 20 hours 10. Patients administered with anetholtrithion within 9.5 hours 11. Patients judged by a physician to be inappropriate for inclusion in the study for any other reason

Study & Design

• Study Type: Interventional
• Study Design: Not specified